{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:59:26Z","timestamp":1790870366657,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032703","name":"BridgeBio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cardfail.2026.02.045","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:52:56Z","timestamp":1778572376000},"page":"864-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial"],"prefix":"10.1016","volume":"32","author":[{"given":"AMRUT V.","family":"AMBARDEKAR","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NITASHA","family":"SARSWAT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RICHARD","family":"WRIGHT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOHN","family":"BERK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARGOT K.","family":"DAVIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PABLO","family":"GARCIA-PAVIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JULIAN D.","family":"GILLMORE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUSTIN L.","family":"GRODIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOSHUA D.","family":"MITCHELL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEIRDRE","family":"MOONEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOSE","family":"NATIVI-NICOLAU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEEN H.","family":"POULSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FREDERICK L.","family":"RUBERG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRIS","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALAN","family":"JI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SURESH","family":"SIDDHANTI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JEAN-FRAN\u00c7OIS","family":"TAMBY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ADAM","family":"CASTA\u00d1O","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LEONID","family":"KATZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"UMA","family":"SINHA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JONATHAN C.","family":"FOX","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MATHEW S.","family":"MAURER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RICHARD K.","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.02.045_bib0001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0002","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nature Rev Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0003","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0004","unstructured":"Jain A, Zahra F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). (Updated April 27, 2023). Treasure Island, FL: StatPearls Publishing,"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0005","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0006","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0008","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0009","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamacardio.2020.5969","article-title":"Association of low plasma transthyretin concentration with risk of heart failure in the general population","volume":"6","author":"Greve","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0012","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13506129.2024.2322479","article-title":"Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I TTR carriers in the general population","volume":"31","author":"Hendren","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0013","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.jchf.2024.06.014","article-title":"Differential association of transthyretin stability with variant and wild-type transthyretin amyloid cardiomyopathy: the SCAN-MP study","volume":"12","author":"Urina-Jassir","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0014","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaccao.2021.08.007","article-title":"Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy","volume":"3","author":"Falk","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0015","unstructured":"BridgeBio Europe B.V. SmPC, Beyonttra (acoramidis). EMA, 2025. Accessed April 02, 2026. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2025\/20250210165087\/anx_165087_en.pdf"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0016","unstructured":"BridgeBio Pharma, Inc. Prescribing Information, Attruby (acoramidis). FDA, 2024. Accessed April 02, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.989","article-title":"Acoramidis produces near-complete TTR stabilization in blood samples from patients with variant transthyretin amyloidosis that is greater than that achieved with tafamidis","volume":"44","author":"Ji","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0018","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0019","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0021","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0022","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.05.015","article-title":"Transthyretin serum levels and clinical outcomes in patients with transthyretin amyloid cardiomyopathy","volume":"142","author":"Minervini","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0024","first-page":"517","volume":"34","author":"Dati","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v059.i05","article-title":"Mediation: R package for causal mediation analysis","volume":"59","author":"Tingley","year":"2014","journal-title":"J Statist Software"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0026","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","article-title":"Mediation analysis: a practitioner\u2019s guide","volume":"37","author":"VanderWeele","year":"2016","journal-title":"Annu Rev Pub Health"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0027","series-title":"Cause of death in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): findings from the ATTRibute-CM study","author":"Obici","year":"2025"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0028","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1038\/s41467-024-50231-1","article-title":"Determinants of transthyretin levels and their association with adverse clinical outcomes among UK Biobank participants","volume":"15","author":"Shetty","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0029","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamacardio.2024.4102","article-title":"Transthyretin tetramer destabilization and increased mortality in the general population","volume":"10","author":"Christoffersen","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/HCO.0000000000001156","article-title":"Treatment of transthyretin cardiac amyloidosis","volume":"39","author":"Bampatsias","year":"2024","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0031","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"Kidney outcomes in transthyretin amyloid cardiomyopathy","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0032","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0033","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jchf.2025.03.017","article-title":"Current landscape of therapies for transthyretin amyloid cardiomyopathy","volume":"13","author":"Griffin","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0034","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cardfail.2025.01.015","article-title":"A question in the era of multiple effective therapies for transthyretin amyloid cardiomyopathy (ATTR-CM): is transthyretin biology a driver of disease progression?","volume":"31","author":"Maurer","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.02.045_bib0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s11684-022-0940-3","article-title":"Plasma transthyretin is a nutritional biomarker in human morbidities","volume":"16","author":"Ingenbleek","year":"2022","journal-title":"Front Med"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642600151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642600151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:59:06Z","timestamp":1783065546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107191642600151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S107191642600151X"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.02.045","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.02.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}